Increase in number of cases for acquired blood coagulating diseases such as hemophilia, Von Willebrand disease are the factors contributing to the market growth. Also, increasing use of thrombin by the patients will drive the thrombin market growth. Increase in the number of accidents and injuries are the factors influencing the market growth. According to WHO report, it is found that 1.35 million individuals die every year, because of street car accidents and 20-50 million additional individuals endure non-lethal wounds, with many acquiring a handicap because of their physical issue this would further contribute to the thrombin market growth.
Companies covered:
- Baxter
- Shanghai RAAS
- Bayer
- Omrix Biopharmaceuticals Ltd.
- CSL
- Octapharma
- Grifols
- Pfizer
- Haematologic Technologies Inc.
- GE Healthcare
- Hualan Biological
In adults, the ordinary blood level of anti-thrombin movement has been estimated to be around 1.1 units/mL. Infant levels of thrombin consistently increment after birth to arrive at typical grown-up levels from a degree of around 0.5 units/mL 1 day after birth to a degree of around 0.9 units/mL following a half year of life. Thrombin collaborates with thrombomodulin to increase the strength of the fibrin.
COVID-19 Scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Key benefits of the report:
- This study presents the analytical depiction of the global thrombin market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints and opportunities along with detailed analysis of the global thrombin market share.
- The current market is quantitatively analyzed from 2020 to 2027 to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the thrombin market.
0 Comments